Table 1 History and Medication Use in the Prior Year among Zoster Cases and Controls
From: Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study
Cases | Controls | |
|---|---|---|
History* | (n = 8900) | (n = 88032) |
Age mean (SD) | 54.7 (24.4) | 54.4 (24.2) |
Gender, male % | 38.6 | 44.4 |
Asthma % | 32.5 | 31.5 |
Asthma exacerbation % | 3.3 | 2.6 |
COPD % | 10.1 | 9.6 |
COPD exacerbation % | 2.2 | 1.7 |
Wheezing % | 5.5 | 4.9 |
Other lung disease % | 2.8 | 2.2 |
Peak Flow test% | 30.1 | 29.2 |
Referral to respiratory physician % | 0.5 | 0.5 |
History of varicella % | 0.2 | 0.2 |
History of zoster % | 0.4 | 0.1 |
Respiratory Hospitalisation % | 1.2 | 0.9 |
Cancer % | 1.9 | 1.2 |
Medications prescribed* | ||
Inhaled Corticosteroids (ICS) % | 47.3 | 46.6 |
Beclometasone % | 36.3 | 36.4 |
Budesonide % | 6.9 | 6.8 |
Fluticasone % | 4.1 | 3.4 |
Other ICS % | 0.1 | 0.1 |
ICS+ Long acting β-agonist % | 11.3 | 9.9 |
Long acting β-agonist % | 7.7 | 7.2 |
Short acting β-agonist % | 61 | 60.1 |
Other respiratory drugs % | 27.7 | 24.6 |
Nasal corticosteroids % | 10.8 | 10 |
Injection corticosteroids % | 1.9 | 1.6 |
Oral corticosteroids % | 19.9 | 15.2 |
Antibiotics % | 61.5 | 52.6 |
Anti-diabetics drugs % | 5.6 | 5 |
Cardiac drugs % | 46.4 | 42.9 |